- Abigail Johnson, the billionaire CEO of Fidelity Investments, has invested mounds of her personal money in Coherus Biosciences, Adaptimmune Therapeutics, ViewRay, and Blueprint Medicines Corp.—all companies focused on oncology R&D.
- Fidelity Investments is the second largest mutual fund company in the world.
- In most cases, Johnson, who is said to be worth $13 billion, got in at the pre-IPO stage.
It should be noted that the investments that Johnson has made in the investments listed above are for her personal accounts. As part of this investment portfolio, Johnson has invested in development of a biosimilar version of Neulasta, which bolsters immunity during chemotherapy.
In addition, through the AdaptImmune investment, Johnson has staked a claim in the development of cancer-fighting therapies that leverage white blood cell activity. Although Johnson has not publicly commented on her personal investing strategies, she clearly has confidence in the biotech sector, with a strong focus on oncology R&D.